Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

• ClinicalTrials.gov Identifier: NCT04180371
• Recruitment Status: Recruiting
• First Posted: November 27, 2019
• Last Update Posted: July 17, 2023
• Sponsor: BicycleTx Limited
• Information provided by (Responsible Party): BicycleTx Limited

Study Description

Brief Summary:

This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to:

• Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab
• Learn more about the side effects of BT5528
• Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer.
• Learn more about BT5528 therapy alone and in combination with nivolumab.

Condition or disease	Intervention/treatment	Phase
Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer; Non-small Cell Lung Cancer; Head and Neck Cancer; Triple Negative Breast Cancer; Gastric/Upper Gastrointestinal Cancer	Drug: BT5528; Drug: Nivolumab	Phase 1; Phase 2

Detailed Description:

BT5528 consists of a bicyclic peptide (Bicycle®) which binds to EphA2, and is covalently attached to a spacer and a protease cleavable peptide linker attached to MMAE.

The Phase I/II multi-center, open-label trial will evaluate BT5528 administered once-weekly as a single agent and in combination with nivolumab. The Phase I portion is a dose escalation primarily designed to assess the safety and tolerability of BT5528 and to determine recommended Phase II dose(s) (RP2D). Following selection of a recommended Phase II dose(s) (RP2D), a dose expansion portion will be initiated with the primary objective of evaluating the clinical activity of BT5528.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 288 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
• Actual Study Start Date: November 7, 2019
• Estimated Primary Completion Date: December 31, 2023
• Estimated Study Completion Date: December 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase I - Dose escalation (BT5528); Cohorts of participants will receive increasing doses of BT5528. It is expected that up to 72 participants will participate in this dose escalation arm.	Drug: BT5528; Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
Experimental: Phase I - Dose escalation combination (BT5528 & nivolumab); Cohorts of participants will receive increasing doses of BT5528 and a standard dose of nivolumab. It is expected that up to 24 participants will participate in this dose-escalation combination arm.	Drug: BT5528; Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.; Drug: Nivolumab; Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.; Other Name: Opdivo
Experimental: Phase II - Dose expansion 1 (BT5528); A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 192 patients have solid tumors (Cohort 1: urothelial cancers, Cohort 2: ovarian cancer, Cohort 3: non-small cell lung cancer, Cohort 4: head and neck cancer, Cohort 5: triple-negative breast cancer, and Cohort 6: gastric/upper gastrointestinal cancer) historically known for high expression of EphA2 will participate in this dose-expansion arm	Drug: BT5528; Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.

Outcome Measures

Primary Outcome Measures :

1. Part A-1 and A-2(escalations): Number of participants receiving BT5528 alone and in combination with nivolumab with treatment-emergent adverse events [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 days post last dose ]
   Safety reported as incidence of treatment-emergent adverse events
2. Part A-1 and A-2 (escalations): Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities from BT5528 treatment alone and in combination with nivolumab [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
   Maximum Tolerated Dose (MTD)
3. Part B: Objective response rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 tumor expression receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment) ]
   Objective Response Rate (ORR)
4. Part B: Duration of response by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment) ]
   Duration of Response (DOR)
5. Part B: Clinical benefit rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment) ]
   Clinical benefit rate
6. Part B: Time to tumor progression by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment) ]
   Time to Progression (TTP)
7. Part B: Progression-free survival by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment) ]
   Progression free survival (PFS)
8. Part B: PFS at 6 months by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months) ]
   Progression free survival (PFS)
9. Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until death or loss of follow-up or withdrawal of consent ]
   Overall survival (OS)

Secondary Outcome Measures :

1. Part A-1 and A-2 (escalations): Objective response rate (ORR) by RECIST 1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
   Objective Response Rate (ORR)
2. Part A-1 and A-2 (escalations): Duration of response (DOR) by RECIST 1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
   Duration of Response (DOR)
3. Part A-1 and A-2 (escalations): Clinical benefit rate (CBR) by RECIST 1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
   Clinical benefit rate (CBR)
4. Part A-1 and A-2 (escalations): Time to tumor progression (TTP) by RECIST 1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
   Time to progression (TTP)
5. Part A-1 and A-2 (escalations): Progression-free survival (PFS) time by RECIST 1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
   Progression free survival (PFS)
6. Part A-1 and A-2 (escalations): Progression free survival at 6 months by RECIST 1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months) ]
   Progression free survival (PFS)
7. Part A-1 and A-2 (escalations): Overall survival time at 12 months in participants with advanced solid tumors with high EphA2 levels receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until death or loss of follow-up or withdrawal of consent (assessed every 3 months up to 12 months ]
   Overall survival (OS)
8. Part B: Determination of the number of participants with advanced solid tumors historically known for high expression of EphA2 receiving BT5528 with treatment-emergent adverse events [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 days post last dose ]
   Safety reported as incidence of treatment-emergent adverse events
9. All parts: Determine the plasma concentrations of BT5528 in plasma from all participants taking BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1,and end of each cycle (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or withdrawal of consent(assessed up to 12 months ]
   plasma concentrations of BT5528 in plasma from all participants taking BT5528 alone and in combination with nivolumab
10. All parts: Determine the plasma concentrations of MMAE in plasma from all participants taking BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1,and end of each cycle (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or withdrawal of consent(assessed up to 12 months ]
    plasma concentrations of MMAE in plasma from all participants taking BT5528 alone and in combination with nivolumab
11. All parts: Number of participants positive for anti-drug antibodies (ADA) from all participants receiving BT5528 alone and in combination with nivolumab [ Time Frame: From Cycle 1,and end of each cycle (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or withdrawal of consent(assessed up to 12 months ]
12. Part B: The association between EphA2 expression level and objective response rate (ORR) per RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
    To investigate if the high expression of EphA2 is associated with high ORR per RECIST 1.1 participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment
13. Part B: The association between EphA2 expression level and duration of response (DOR) by RECIST 1.1 and per EphA2 expression in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
    To investigate if the high expression of EphA2 is associated with high DOR per RECIST 1.1 participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment
14. Part B: The association between EphA2 expression level and clinical benefit rate (CBR) per RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
    To investigate if the high expression of EphA2 is associated with high CBR per RECIST 1.1 participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment
15. Part B: The association between EphA2 expression level and time to tumor progression (TTP) per RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
    To investigate if the high expression of EphA2 is associated with long TTP per RECIST 1.1 participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment
16. Part B: The association between EphA2 expression level and progression-free survival (PFS) at 6 months by RECIST 1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months then every 16 weeks up to 12 months ]
    To investigate if the high expression of EphA2 is associated with long PFS at 6 months per RECIST 1.1 participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment
17. Part B: The association between EphA2 expression level and overall survival (OS) at 1 year by RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment [ Time Frame: From Cycle 1 Day 1 (each cycle is 28 days) until death or loss of follow-up or withdrawal of consent (assessed every 3 months up to 12 months) ]
    To investigate if the high expression of EphA2 is associated with long OS at 1 year per RECIST 1.1 participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

General Inclusion:

• Written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling or analyses
• At least 18 years-of-age at the time of signature of the informed consent form
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Acceptable renal, hepatic, hematologic and coagulation functions
• Negative pregnancy test for women of childbearing potential
• Male participants with female partners of childbearing potential and female participants of childbearing potential are required to follow highly effective contraception
• All patients must have tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers. In the absence of available tumor tissue, patients must be willing to undergo a biopsy to provide fresh tumor samples
• Life expectancy ≥12 weeks after the start of BT5528 treatment according to the Investigator's judgment.
• Must be willing and able to comply with the protocol and study procedures.

Additional inclusion criteria for Phase I (dose escalation phase, with BT5528 alone or in combination with nivolumab):

• Metastatic recurrent histologically confirmed malignant solid tumors historically known for high EphA2 tumor expression. Confirmation of EphA2 expression prior to enrollment is not required for participants with ovarian cancer and specific other individual tumor types.
• Exhausted all appropriate treatment options per local guidelines

Additional inclusion criteria for Phase II (dose expansion phase, with BT5528 alone):

• Participants with metastatic recurrent disease histologically confirmed to be non-small cell lung cancer, ovarian cancer, triple-negative breast cancer (TNBC), gastric/upper gastrointestinal (GI) cancer, head and neck (H&N) cancer, urothelial cancer are eligible and must have failed or are ineligible for all appropriate treatment options per local guidelines and must have evidence of radiographic progression on the most recent line of therapy
• Patients with urothelial cancer who have previously received treatment with enfortumab vedotin (EV) are eligible to the study. Patients who received EV and showed disease progression within 6 months of treatment start are planned for less than 50% of total patients enrolled in the cohort

Exclusion criteria (all participants):

• Chemotherapy treatments within 14 days prior to first dose of study treatment, other anticancer treatments, treatment within 28 days or 5 half-lives, whichever is the shorter
• Experimental treatments within 4 weeks of first dose of BT5528
• Prior toxicities must have resolved to Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 (except alopecia which can be Grade 2)
• Current treatment with strong inhibitors or inducers of CYP3A4 or strong inhibitors of P-gp
• Known sensitivity to any of the ingredients of the investigational product or monomethyl auristatin E (MMAE)
• Any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or is not in the best interest of the patient to participate in the opinion of the investigator including but not limited to specific cardiovascular criteria
• Major surgery (excluding placement of vascular access) within 4 weeks of first dose of BT5528 study treatment and must have recovered adequately prior to starting study therapy
• Receipt of live vaccine within 30 days of study treatment
• Untreated CNS metastases or leptomeningeal disease
• Uncontrolled hypertension (systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg that is not responsive to intervention) at screening or prior to initiation of study drug.

• History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or is not in the best interest of the patient to participate in the opinion of the Investigator including but not limited to:

  (a) Patients with history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, congestive heart failure or symptoms of New York Heart Association Class III-IV documented within 6 months prior to first dose of BT5528 or: (i) Mean resting corrected QT interval (QTcF) >470 msec (ii) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval (iii) Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting electrocardiograms (ECGs), e.g., complete left bundle branch block, third degree heart block

• Known human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS). Note: Well controlled HIV will be allowed if the patient meets all the following criteria at inclusion:

  1. CD4+ T-cell (CD4+) counts ≥350 cells/uL;
  2. HIV viral load <400 copies/mL
  3. Without a history of opportunistic infection within the last 12 months.
  4. On established antiretroviral therapy (ART) for at least 4 weeks. Use of anti-retroviral therapy is permitted, but should be discussed with the Medical Monitor on a case-by-case basis.
• Patients with a positive hepatitis B surface antigen and/or anti-hepatitis B core antibody. Patients with a negative polymerase chain reaction (PCR) assay are permitted with appropriate antiviral therapy
• Active hepatitis C infection with positive viral load if hepatitis C virus (HCV) antibody positive (if antibody is negative then viral load not applicable). Patients who have been treated for hepatitis C infection can be included if they have documented sustained virologic response of ≥12 weeks.
• Thromboembolic events and/or bleeding disorders 3 months (e.g., deep vein thrombosis [DVT] or pulmonary embolism [PE]) prior to first dose
• Prior history of pneumonitis with presence of residual symptoms
• History of another malignancy within 3 years before the first dose of BT5528, or any evidence of residual disease from a previously diagnosed malignancy (excluding adequately treated with curative intent basal cell carcinoma, squamous cell of the skin, cervical intraepithelial neoplasia/cervical carcinoma in situ or melanoma in situ or ductal carcinoma in situ of the breast).
• Systemic anti-infective treatment or fever within the last 14 days prior to first dose of BT5528 study treatment
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

Additional Exclusion Criteria (BT5528 in combination with nivolumab):

• Prior intolerance to immune checkpoint inhibitor
• Known hypersensitivity to checkpoint inhibitor therapy
• Prior organ transplant (including allogeneic)
• Diagnosis of clinically relevant immunodeficiency
• Active systemic infection requiring therapy
• More than 10 mg daily prednisone equivalent or other strong immunosuppressant
• History of autoimmune disease except alopecia or vitiligo
• History of interstitial lung disease

Contacts and Locations

Contacts

Contact: BicycleTx Limited; 617-945-8155; clinicalstudies@bicycletx.com

Locations

United States, California

California Cancer Associates for Research and Excellence, Inc.; Recruiting

Encinitas, California, United States, 92024

Principal Investigator: Alberto Bessudo, MD

University of California, San Diego (UCSD) - Medical Center; Recruiting

La Jolla, California, United States, 92037

Principal Investigator: Shumei Kato, MD

University of California - Irvine Medical Center; Recruiting

Orange, California, United States, 92868

Principal Investigator: Misako Nagasaka, MD

United States, Colorado

Sarah Cannon Research Institute at HealthONE; Recruiting

Denver, Colorado, United States, 80218

Principal Investigator: Gerald Falchook, MD, MS

United States, Florida

Florida Cancer Specialists; Recruiting

Sarasota, Florida, United States, 34232

Principal Investigator: Judy Wang, MD

United States, Massachusetts

Dana Farber Cancer Institute; Withdrawn

Boston, Massachusetts, United States, 02215

United States, Michigan

Barbara Ann Karmanos Cancer Institute; Recruiting

Detroit, Michigan, United States, 48201

Principal Investigator: Hirva Mamdani, MD

United States, Nevada

Comprehensive Cancer Centers of Nevada; Completed

Las Vegas, Nevada, United States, 89169

United States, New York

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center; Recruiting

New York, New York, United States, 10021

Principal Investigator: Min-Yuen Teo, MD

United States, Oklahoma

Stephenson Cancer Center (Oklahoma University); Recruiting

Oklahoma City, Oklahoma, United States, 73104

Principal Investigator: Raid Aljumaily, MD

United States, Pennsylvania

Sidney Kimmel Cancer Center at Thomas Jefferson University; Recruiting

Philadelphia, Pennsylvania, United States, 19107

Principal Investigator: Babar Bashir, MD

United States, Rhode Island

Women and Infants Hospital; Recruiting

Providence, Rhode Island, United States, 02905

Principal Investigator: Matthews Cara, MD

United States, Tennessee

Tennessee Oncology, PLLC; Recruiting

Nashville, Tennessee, United States, 37221

Principal Investigator: Meredith McKean, MD, MPH

United States, Texas

MD Anderson Cancer Center; Recruiting

Houston, Texas, United States, 77030

Principal Investigator: Jordi Rodon Ahnert, MD

United States, Virginia

Virginia Cancer Specialists; Recruiting

Fairfax, Virginia, United States, 22031

Principal Investigator: Alexander Spira, MD

United States, Wisconsin

Froedtert Hospital and the Medical College of Wisconsin; Recruiting

Milwaukee, Wisconsin, United States, 53226

Principal Investigator: Jonathan Thompson, MD

Belgium

Institut Jules Bordet; Recruiting

Brussels, Belgium, 1070

Principal Investigator: Dr. Nuria Kotecki

Cliniques Universitaires Saint-Luc; Recruiting

Bruxelles, Belgium

Principal Investigator: Jean-Pascal Machiels, MD,PhD

Antwerp University Hospital (UZA); Recruiting

Edegem, Belgium

Principal Investigator: Hans Prenen, MD, PhD

Universitair Ziekenhuis Gent (UZ); Recruiting

Gent, Belgium, 9000

Principal Investigator: Dr. Sylvie Rottey

Korea, Republic of

Gachon University Gil Medical Center; Recruiting

Incheon, Korea, Republic of, 21565

Principal Investigator: Joo-Hwan Park, MD

Severance Hospital, Yonsei University Health System; Recruiting

Seoul, Korea, Republic of, 3722

Principal Investigator: Sang Wun Kim, MD

Spain

Institut Catala d'Oncologia - L'Hospitalet; Recruiting

Barcelona, Spain, 08908

Principal Investigator: Juan Martin Liberal

Hospital Universitario Vall d'Hebron; Recruiting

Barcelona, Spain, 8035

Principal Investigator: Elena Garralda Cabanas, MD

Hospital Fundación Jimenez Diaz; Recruiting

Madrid, Spain, 28040

Principal Investigator: Bernard Doger de Speville, MD

Hospital Universitario 12 de Octubre; Recruiting

Madrid, Spain, 28041

Principal Investigator: Luis Paz-Ares Rodriguez, MD

Centro Integral Oncologico Clara Campal; Recruiting

Madrid, Spain, 28050

Principal Investigator: Emiliano Calvo Aller, MD

United Kingdom

Cambridge University Hospitals NHS Foundation Trust; Recruiting

Cambridge, United Kingdom, CB2 0QQ

Principal Investigator: Bristi Basu, MD

The Leeds Teaching Hospitals NHS Trust Of Trust Headquarters, St James's University Hospital; Recruiting

Leeds, United Kingdom, LS9 7TF

Principal Investigator: Fiona Collinson, MD

Sarah Cannon Research Institute UK; Recruiting

London, United Kingdom, W1G 6AD

Principal Investigator: Elisa Fontana, MD

The Christie NHS Foundation Trust; Recruiting

Manchester, United Kingdom, M20 4BX

Principal Investigator: Louise Carter, MBBS, PhD

Sir Bobby Robson Cancer Trials Research Centre, The Northern Center for Cancer Care, Freeman Hospital; Recruiting

Newcastle Upon Tyne, United Kingdom, NE7 7DN

Principal Investigator: Dr. Alistair Greystoke

Sponsors and Collaborators

BicycleTx Limited

Investigators

• Study Chair: Meredith McKean, MD, MPH; Sarah Cannon Research Institute Tennessee Oncology

More Information

• Responsible Party: BicycleTx Limited
• ClinicalTrials.gov Identifier: NCT04180371
• Other Study ID Numbers: BT5528-100
• First Posted: November 27, 2019
• Last Update Posted: July 17, 2023
• Last Verified: July 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by BicycleTx Limited:

EphA2; ovarian cancer; urothelial cancer; bladder cancer; NSCLC; TNBC; gastric cancer; GEJ cancer; HNSCC

Additional relevant MeSH terms:

Ovarian Neoplasms; Triple Negative Breast Neoplasms; Gastrointestinal Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Breast Neoplasms; Breast Diseases; Skin Diseases; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Nivolumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action